Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Sentinel lymph node biopsy for in situ melanoma is unlikely in Australia.

Morton RL, Thompson JF.

BMJ Qual Saf. 2019 Jan 3. pii: bmjqs-2018-009138. doi: 10.1136/bmjqs-2018-009138. [Epub ahead of print] No abstract available.

PMID:
30606805
2.

Effectiveness of Screening and Treatment Approaches for Schistosomiasis and Strongyloidiasis in Newly-Arrived Migrants from Endemic Countries in the EU/EEA: A Systematic Review.

Agbata EN, Morton RL, Bisoffi Z, Bottieau E, Greenaway C, Biggs BA, Montero N, Tran A, Rowbotham N, Arevalo-Rodriguez I, Myran DT, Noori T, Alonso-Coello P, Pottie K, Requena-Méndez A.

Int J Environ Res Public Health. 2018 Dec 20;16(1). pii: E11. doi: 10.3390/ijerph16010011. Review.

3.

An International Analysis of Dialysis Services Reimbursement.

van der Tol A, Lameire N, Morton RL, Van Biesen W, Vanholder R.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):84-93. doi: 10.2215/CJN.08150718. Epub 2018 Dec 13.

PMID:
30545819
4.

The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Population-based data on diagnosis and management.

Guitera P, Collgros H, Madronio CM, Goumas C, Mann GJ, Watts CG, Pereira AR, Armstrong BK, Drummond M, Morton RL, Scolyer RA, Menzies SW, Thompson JF, Cust AE.

Australas J Dermatol. 2018 Oct 9. doi: 10.1111/ajd.12928. [Epub ahead of print]

PMID:
30302753
5.

The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review.

Greenaway C, Makarenko I, Chakra CNA, Alabdulkarim B, Christensen R, Palayew A, Tran A, Staub L, Pareek M, Meerpohl JJ, Noori T, Veldhuijzen I, Pottie K, Castelli F, Morton RL.

Int J Environ Res Public Health. 2018 Sep 14;15(9). pii: E2013. doi: 10.3390/ijerph15092013. Review.

6.

Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).

Mersiades AJ, Tognela A, Haber PS, Stockler M, Lintzeris N, Simes J, McGregor I, Olver I, Allsop DJ, Gedye C, Kirby AC, Morton RL, Fox P, Clarke S, Briscoe K, Aghmesheh M, Wong N, Walsh A, Hahn C, Grimison P.

BMJ Open. 2018 Sep 12;8(9):e020745. doi: 10.1136/bmjopen-2017-020745.

7.

Physical component Quality of life (QOL) reflects the impact of time and moderate chronic kidney disease, unlike SF-6D utility and mental component SF-36 QOL: an AUSDiab analysis.

Wong MG, Ninomiya T, Liyanage T, Sukkar L, Hirakawa Y, Wang Y, Wyld ML, Morton RL, Chadban S, Howard K, Jardine MJ.

Nephrology (Carlton). 2018 Jul 24. doi: 10.1111/nep.13445. [Epub ahead of print]

PMID:
30039893
8.

Use of shared care and routine tests in follow-up after treatment for localised cutaneous melanoma.

Lim WY, Turner RM, Morton RL, Jenkins MC, Irwig L, Webster AC, Dieng M, Saw RPM, Guitera P, Low D, Low C, Bell KJL.

BMC Health Serv Res. 2018 Jun 20;18(1):477. doi: 10.1186/s12913-018-3291-7.

9.

Impact of CKD on Household Income.

Morton RL, Schlackow I, Gray A, Emberson J, Herrington W, Staplin N, Reith C, Howard K, Landray MJ, Cass A, Baigent C, Mihaylova B; SHARP Collaborative Group.

Kidney Int Rep. 2017 Dec 23;3(3):610-618. doi: 10.1016/j.ekir.2017.12.008. eCollection 2018 May.

10.

The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors.

Smit AK, Newson AJ, Morton RL, Kimlin M, Keogh L, Law MH, Kirk J, Dobbinson S, Kanetsky PA, Fenton G, Allen M, Butow P, Dunlop K, Trevena L, Lo S, Savard J, Dawkins H, Wordsworth S, Jenkins M, Mann GJ, Cust AE.

Contemp Clin Trials. 2018 Jul;70:106-116. doi: 10.1016/j.cct.2018.05.014. Epub 2018 May 23.

PMID:
29802966
11.

The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review.

Greenaway C, Pareek M, Abou Chakra CN, Walji M, Makarenko I, Alabdulkarim B, Hogan C, McConnell T, Scarfo B, Christensen R, Tran A, Rowbotham N, van der Werf MJ, Noori T, Pottie K, Matteelli A, Zenner D, Morton RL.

Euro Surveill. 2018 Apr;23(14). doi: 10.2807/1560-7917.ES.2018.23.14.17-00543.

12.

The effectiveness and cost-effectiveness of screening for active tuberculosis among migrants in the EU/EEA: a systematic review.

Greenaway C, Pareek M, Abou Chakra CN, Walji M, Makarenko I, Alabdulkarim B, Hogan C, McConnell T, Scarfo B, Christensen R, Tran A, Rowbotham N, Noori T, van der Werf MJ, Pottie K, Matteelli A, Zenner D, Morton RL.

Euro Surveill. 2018 Apr;23(14). doi: 10.2807/1560-7917.ES.2018.23.14.17-00542.

13.

Patient Preferences for Follow-up After Recent Excision of a Localized Melanoma.

Lim WY, Morton RL, Turner RM, Jenkins MC, Guitera P, Irwig L, Webster AC, Dieng M, Saw RPM, Low D, Low C, Bell KJL.

JAMA Dermatol. 2018 Apr 1;154(4):420-427. doi: 10.1001/jamadermatol.2018.0021.

PMID:
29490373
14.

A case-control study of end-of-life treatment preferences and costs following advance care planning for adults with end stage kidney disease.

Sellars M, Morton RL, Clayton JM, Tong A, Mawren D, Silvester W, Power D, Ma R, Detering KM.

Nephrology (Carlton). 2018 Feb 1. doi: 10.1111/nep.13230. [Epub ahead of print]

PMID:
29389053
15.

A National Budget Impact Analysis of a Specialised Surveillance Programme for Individuals at Very High Risk of Melanoma in Australia.

Watts CG, Wortley S, Norris S, Menzies SW, Guitera P, Askie L, Mann GJ, Morton RL, Cust AE.

Appl Health Econ Health Policy. 2018 Apr;16(2):235-242. doi: 10.1007/s40258-017-0368-0.

PMID:
29305821
16.

Follow-Up Recommendations after Diagnosis of Primary Cutaneous Melanoma: A Population-Based Study in New South Wales, Australia.

Read RL, Madronio CM, Cust AE, Goumas C, Watts CG, Menzies S, Curtin AM, Mann G, Thompson JF, Morton RL.

Ann Surg Oncol. 2018 Mar;25(3):617-625. doi: 10.1245/s10434-017-6319-z. Epub 2018 Jan 3.

PMID:
29299710
17.

Sensitivity of Preference-Based Quality-of-Life Measures for Economic Evaluations in Early-Stage Melanoma.

Dieng M, Kasparian NA, Cust AE, Costa DSJ, Tran A, Butow PN, Menzies SW, Mann GJ, Morton RL.

JAMA Dermatol. 2018 Jan 1;154(1):52-59. doi: 10.1001/jamadermatol.2017.4701.

18.

An Interview Study of Patient and Caregiver Perspectives on Advance Care Planning in ESRD.

Sellars M, Clayton JM, Morton RL, Luckett T, Silvester W, Spencer L, Pollock CA, Walker RG, Kerr PG, Tong A.

Am J Kidney Dis. 2018 Feb;71(2):216-224. doi: 10.1053/j.ajkd.2017.07.021. Epub 2017 Nov 11.

PMID:
29132946
19.

Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion.

Critselis E, Vlahou A, Stel VS, Morton RL.

Nephrol Dial Transplant. 2018 Mar 1;33(3):441-449. doi: 10.1093/ndt/gfx068.

PMID:
29106632
20.

A systematic review and meta-analysis of utility estimates in melanoma.

Tran AD, Fogarty G, Nowak AK, Espinoza D, Rowbotham N, Stockler MR, Morton RL.

Br J Dermatol. 2018 Feb;178(2):384-393. doi: 10.1111/bjd.16098. Epub 2018 Jan 17. Review.

PMID:
29077983
21.

A Discrete Choice Study of Patient Preferences for Dialysis Modalities.

Walker RC, Morton RL, Palmer SC, Marshall MR, Tong A, Howard K.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):100-108. doi: 10.2215/CJN.06830617. Epub 2017 Oct 19.

22.

Further approaches to reduce the cost of renal replacement therapy.

Vanholder R, Annemans L, Brown E, Gansevoort R, Gout-Zwart JJ, Lameire N, Morton RL, Oberbauer R, Postma MJ, Tonelli M, Van Biesen W, Zoccali C; European Kidney Health Alliance.

Nat Rev Nephrol. 2017 Nov;13(11):720. doi: 10.1038/nrneph.2017.136. Epub 2017 Sep 25. No abstract available.

PMID:
28944776
23.

Prevention and assessment of infectious diseases among children and adult migrants arriving to the European Union/European Economic Association: a protocol for a suite of systematic reviews for public health and health systems.

Pottie K, Mayhew AD, Morton RL, Greenaway C, Akl EA, Rahman P, Zenner D, Pareek M, Tugwell P, Welch V, Meerpohl J, Alonso-Coello P, Hui C, Biggs BA, Requena-Méndez A, Agbata E, Noori T, Schünemann HJ.

BMJ Open. 2017 Sep 11;7(9):e014608. doi: 10.1136/bmjopen-2016-014608.

24.

Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis.

Herzog S, Shanahan M, Grimison P, Tran A, Wong N, Lintzeris N, Simes J, Stockler M, Morton RL.

Pharmacoeconomics. 2018 Jan;36(1):67-78. doi: 10.1007/s40273-017-0565-6. Review.

PMID:
28866778
25.

A review of international clinical practice guidelines for the use of oxygen in the delivery room resuscitation of preterm infants.

Wilson A, Vento M, Shah PS, Saugstad O, Finer N, Rich W, Morton RL, Rabi Y, Tarnow-Mordi W, Suzuki K, Wright IM, Oei JL.

Acta Paediatr. 2018 Jan;107(1):20-27. doi: 10.1111/apa.14012. Epub 2017 Sep 6. Review.

PMID:
28792628
26.

Does personalized melanoma genomic risk information trigger conversations about skin cancer prevention and skin examination with family, friends and health professionals?

Smit AK, Keogh LA, Newson AJ, Butow PN, Dunlop K, Morton RL, Kirk J, Espinoza D, Cust AE.

Br J Dermatol. 2017 Sep;177(3):779-790. doi: 10.1111/bjd.15744. Epub 2017 Jul 20.

PMID:
28627002
27.

Reducing the costs of chronic kidney disease while delivering quality health care: a call to action.

Vanholder R, Annemans L, Brown E, Gansevoort R, Gout-Zwart JJ, Lameire N, Morton RL, Oberbauer R, Postma MJ, Tonelli M, Biesen WV, Zoccali C; European Kidney Health Alliance.

Nat Rev Nephrol. 2017 Jul;13(7):393-409. doi: 10.1038/nrneph.2017.63. Epub 2017 May 30. Review.

PMID:
28555652
28.

GRADE equity guidelines 3: considering health equity in GRADE guideline development: rating the certainty of synthesized evidence.

Welch VA, Akl EA, Pottie K, Ansari MT, Briel M, Christensen R, Dans A, Dans L, Eslava-Schmalbach J, Guyatt G, Hultcrantz M, Jull J, Katikireddi SV, Lang E, Matovinovic E, Meerpohl JJ, Morton RL, Mosdol A, Murad MH, Petkovic J, Schünemann H, Sharaf R, Shea B, Singh JA, Solà I, Stanev R, Stein A, Thabaneii L, Tonia T, Tristan M, Vitols S, Watine J, Tugwell P.

J Clin Epidemiol. 2017 Oct;90:76-83. doi: 10.1016/j.jclinepi.2017.01.015. Epub 2017 Apr 4.

29.

Optimising care for children with kidney disease.

Caskey FJ, Morton RL.

Lancet. 2017 May 27;389(10084):2084-2086. doi: 10.1016/S0140-6736(17)30267-2. Epub 2017 Mar 20. No abstract available.

PMID:
28336051
30.

Quality of Life Following Sentinel Node Biopsy for Primary Cutaneous Melanoma: Health Economic Implications.

Morton RL, Tran A, Vessey JY, Rowbotham N, Winstanley J, Shannon K, Spillane AJ, Stretch J, Thompson JF, Saw RP.

Ann Surg Oncol. 2017 Aug;24(8):2071-2079. doi: 10.1245/s10434-017-5842-2. Epub 2017 Mar 20.

PMID:
28321690
31.

Home hemodialysis: a comprehensive review of patient-centered and economic considerations.

Walker RC, Howard K, Morton RL.

Clinicoecon Outcomes Res. 2017 Feb 16;9:149-161. doi: 10.2147/CEOR.S69340. eCollection 2017. Review.

32.

Clinicians' Perspectives on Advance Care Planning for Patients With CKD in Australia: An Interview Study.

Sellars M, Tong A, Luckett T, Morton RL, Pollock CA, Spencer L, Silvester W, Clayton JM.

Am J Kidney Dis. 2017 Sep;70(3):315-323. doi: 10.1053/j.ajkd.2016.11.023. Epub 2017 Feb 17.

PMID:
28216281
33.

Measuring trade-offs in nephrology: a systematic review of discrete choice experiments and conjoint analysis studies.

Clark MD, Szczepura A, Gumber A, Howard K, Moro D, Morton RL.

Nephrol Dial Transplant. 2018 Feb 1;33(2):348-355. doi: 10.1093/ndt/gfw436.

PMID:
28158746
34.

Māori patients' experiences and perspectives of chronic kidney disease: a New Zealand qualitative interview study.

Walker RC, Walker S, Morton RL, Tong A, Howard K, Palmer SC.

BMJ Open. 2017 Jan 19;7(1):e013829. doi: 10.1136/bmjopen-2016-013829.

35.

Fear of new or recurrent melanoma after treatment for localised melanoma.

Bell KJL, Mehta Y, Turner RM, Morton RL, Dieng M, Saw R, Guitera P, McCaffery K, Low D, Low C, Jenkins M, Irwig L, Webster AC.

Psychooncology. 2017 Nov;26(11):1784-1791. doi: 10.1002/pon.4366. Epub 2017 Feb 2.

PMID:
28052599
36.

Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.

Watts CG, Cust AE, Menzies SW, Mann GJ, Morton RL.

J Clin Oncol. 2017 Jan;35(1):63-71. Epub 2016 Oct 28.

PMID:
28034073
37.

Psychoeducational Intervention to Reduce Fear of Cancer Recurrence in People at High Risk of Developing Another Primary Melanoma: Results of a Randomized Controlled Trial.

Dieng M, Butow PN, Costa DS, Morton RL, Menzies SW, Mireskandari S, Tesson S, Mann GJ, Cust AE, Kasparian NA.

J Clin Oncol. 2016 Dec 20;34(36):4405-4414. Epub 2016 Oct 28.

PMID:
27998215
38.

Chronic Kidney Disease.

Webster AC, Nagler EV, Morton RL, Masson P.

Lancet. 2017 Mar 25;389(10075):1238-1252. doi: 10.1016/S0140-6736(16)32064-5. Epub 2016 Nov 23. Review.

PMID:
27887750
39.

Protocol for a within-trial economic evaluation of a psychoeducational intervention tailored to people at high risk of developing a second or subsequent melanoma.

Dieng M, Cust AE, Kasparian NA, Butow P, Costa DS, Menzies SW, Mann GJ, Morton RL.

BMJ Open. 2016 Oct 6;6(10):e012153. doi: 10.1136/bmjopen-2016-012153.

40.

Clinical Features Associated With Individuals at Higher Risk of Melanoma: A Population-Based Study.

Watts CG, Madronio C, Morton RL, Goumas C, Armstrong BK, Curtin A, Menzies SW, Mann GJ, Thompson JF, Cust AE.

JAMA Dermatol. 2017 Jan 1;153(1):23-29. doi: 10.1001/jamadermatol.2016.3327.

PMID:
27829101
41.

A Pilot Randomized Controlled Trial of the Feasibility, Acceptability, and Impact of Giving Information on Personalized Genomic Risk of Melanoma to the Public.

Smit AK, Espinoza D, Newson AJ, Morton RL, Fenton G, Freeman L, Dunlop K, Butow PN, Law MH, Kimlin MG, Keogh LA, Dobbinson SJ, Kirk J, Kanetsky PA, Mann GJ, Cust AE.

Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):212-221. doi: 10.1158/1055-9965.EPI-16-0395. Epub 2016 Oct 4.

42.

Conservative Management and End-of-Life Care in an Australian Cohort with ESRD.

Morton RL, Webster AC, McGeechan K, Howard K, Murtagh FE, Gray NA, Kerr PG, Germain MJ, Snelling P.

Clin J Am Soc Nephrol. 2016 Dec 7;11(12):2195-2203. Epub 2016 Oct 3.

43.

Doctors' recognition and management of melanoma patients' risk: An Australian population-based study.

Madronio CM, Armstrong BK, Watts CG, Goumas C, Morton RL, Curtin A, Menzies SW, Mann GJ, Thompson JF, Cust AE.

Cancer Epidemiol. 2016 Dec;45:32-39. doi: 10.1016/j.canep.2016.09.006. Epub 2016 Sep 28.

PMID:
27689254
44.

"Who matters most?": Clinician perspectives of influence and recommendation on home dialysis uptake.

Walker RC, Marshall R, Howard K, Morton RL, Marshall MR.

Nephrology (Carlton). 2017 Dec;22(12):977-984. doi: 10.1111/nep.12920.

PMID:
27599361
45.

Social Dancing and Incidence of Falls in Older Adults: A Cluster Randomised Controlled Trial.

Merom D, Mathieu E, Cerin E, Morton RL, Simpson JM, Rissel C, Anstey KJ, Sherrington C, Lord SR, Cumming RG.

PLoS Med. 2016 Aug 30;13(8):e1002112. doi: 10.1371/journal.pmed.1002112. eCollection 2016 Aug.

46.

Patient Education and Choice of Peritoneal Dialysis.

Walker RC, Howard K, Morton RL.

Am J Kidney Dis. 2016 Sep;68(3):341-3. doi: 10.1053/j.ajkd.2016.06.007. No abstract available.

PMID:
27561667
47.

Supportive Care: Economic Considerations in Advanced Kidney Disease.

Morton RL, Kurella Tamura M, Coast J, Davison SN.

Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1915-1920. doi: 10.2215/CJN.12651115. Epub 2016 Aug 10. Review.

48.

Supportive Care: Comprehensive Conservative Care in End-Stage Kidney Disease.

Murtagh FE, Burns A, Moranne O, Morton RL, Naicker S.

Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1909-1914. doi: 10.2215/CJN.04840516. Epub 2016 Aug 10.

49.

How Qualitative Research Informs Clinical and Policy Decision Making in Transplantation: A Review.

Tong A, Morton RL, Webster AC.

Transplantation. 2016 Sep;100(9):1997-2005. doi: 10.1097/TP.0000000000001358. Review.

PMID:
27479165
50.

Diagnosis and clinical management of melanoma patients at higher risk of a new primary melanoma: A population-based study in New South Wales, Australia.

Watts CG, Madronio CM, Morton RL, Goumas C, Armstrong BK, Curtin A, Menzies SW, Mann GJ, Thompson JF, Cust AE.

Australas J Dermatol. 2017 Nov;58(4):278-285. doi: 10.1111/ajd.12530. Epub 2016 Aug 1.

PMID:
27477217

Supplemental Content

Loading ...
Support Center